<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086969</url>
  </required_header>
  <id_info>
    <org_study_id>MTA51</org_study_id>
    <secondary_id>UTN: U1111-1111-5608</secondary_id>
    <nct_id>NCT01086969</nct_id>
  </id_info>
  <brief_title>A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India</brief_title>
  <official_title>Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects 2-55 Years of Age in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of a single dose of
      Menactra® vaccine to support registration.

      Primary Objectives:

        -  To describe the antibody titers measured by serum bactericidal activity using baby
           rabbit complement (SBA-BR) before and after Menactra® vaccination.

        -  To describe the safety profile of participants after one dose of Menactra®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be enrolled in three age cohorts: Children: 2 - 11 years of age;
      Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age to receive a single dose
      of Menactra®. They will be followed for a duration of 30 days after vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination</measure>
    <time_frame>Baseline and 21 days post-vaccination</time_frame>
    <description>Antibodies to Menactra vaccine were measured by the Serum bactericidal assay baby rabbit complement (SBA BR) Test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Baby Rabbit Complement (SBA BR) Geometric Mean Titers Before and Post Menactra Vaccination</measure>
    <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
    <description>Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least a 4-fold Increase in Antibodies to Menactra Vaccine Antigens Post Vaccination</measure>
    <time_frame>Day 0 to 30 post-vaccination</time_frame>
    <description>Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Menactra Vaccination</measure>
    <time_frame>Day 0 to 7 post-vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema (Redness), and Swelling. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Meningococcal Infection</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 2 to 11 years or Aged 12 to 17 years or Aged 18 to 55 years of age on the day of
             inclusion

          -  For participants aged 2 to 11 years: Provision of informed consent form signed by the
             parent(s) or legal representative.

          -  For participants aged 12 to 17 years: Provision of assent form signed by the
             participant and informed consent form signed by the parent(s) or legal representative.

          -  For participants aged 18 to 55 years: Provision of informed consent form signed by the
             participant. If the participant or the participant's parents or legally accepted
             representative (participants aged 2 to 17 years) are illiterate, an independent
             witness is required to sign the consent form.

          -  Participant and parent/legally acceptable representative (if applicable) able to
             attend all scheduled visits and comply with all trial procedures

          -  For a woman of child-bearing potential, sexually active, use of a medically acceptable
             and effective method of contraception for at least 4 weeks prior to vaccination, until
             at least 4 weeks after vaccination (not applicable for participants aged 2 to 17
             years' females not of child-bearing potential or not sexually active)

        Exclusion Criteria :

          -  For a woman of child-bearing potential sexually active, known or suspected pregnancy
             or positive serum/urine pregnancy test (not applicable for participants aged 2 to 17
             years' females not of child-bearing potential or not sexually active)

          -  Breast-feeding woman

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the
             same substances

          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in
             the opinion of the investigator

          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability
             to comply with trial procedures

          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere
             with the assessment of immune response

          -  Receipt or planned receipt of any vaccine (other than influenza vaccine which can be
             given 2 weeks or more before vaccination) in the 4 weeks preceding or following the
             trial vaccination

          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen , or
             Hepatitis C seropositivity as reported by the participant/parent/guardian and/or based
             on medical history

          -  History of documented invasive meningococcal disease

          -  Previous vaccination against meningococcal disease with either the trial vaccine or
             another vaccine

          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding
             inclusion contraindicating intramuscular vaccination

          -  Subjects deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent

          -  Personal or family history of Guillain-Barré Syndrome

        Temporary contraindications delaying vaccination until resolved:

          -  Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on
             the day of vaccination

          -  Received oral or injected antibiotic therapy within the 72 hours prior to any blood
             draw
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <zip>560070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <results_first_submitted>January 3, 2012</results_first_submitted>
  <results_first_submitted_qc>January 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2012</results_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal Infection</keyword>
  <keyword>Meningitis, Bacterial</keyword>
  <keyword>Menactra®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 11 June to 01 October 2010 in 3 clinical centers in India.</recruitment_details>
      <pre_assignment_details>A total of 300 participants that met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Age 2 to 11 Years Group</title>
          <description>Participants at age 2 to 11 years on enrollment.</description>
        </group>
        <group group_id="P2">
          <title>Age 12 to 17 Years Group</title>
          <description>Participants aged 12 to 17 years at enrollment.</description>
        </group>
        <group group_id="P3">
          <title>Age 18 to 55 Years Group</title>
          <description>Participants aged 18 to 55 years at enrollment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age 2 to 11 Years Group</title>
          <description>Participants at age 2 to 11 years on enrollment.</description>
        </group>
        <group group_id="B2">
          <title>Age 12 to 17 Years Group</title>
          <description>Participants aged 12 to 17 years at enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Age 18 to 55 Years Group</title>
          <description>Participants aged 18 to 55 years at enrollment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="3.1"/>
                    <measurement group_id="B2" value="14.2" spread="1.4"/>
                    <measurement group_id="B3" value="34.8" spread="9.2"/>
                    <measurement group_id="B4" value="18.7" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination</title>
        <description>Antibodies to Menactra vaccine were measured by the Serum bactericidal assay baby rabbit complement (SBA BR) Test.</description>
        <time_frame>Baseline and 21 days post-vaccination</time_frame>
        <population>Menactra vaccine antibody titers were determined in the immunogenicity analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2 to 11 Years Group</title>
            <description>Participants at age 2 to 11 years on enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Age 12 to 17 Years Group</title>
            <description>Participants aged 12 to 17 years at enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Age 18 to 55 Years Group</title>
            <description>Participants aged 18 to 55 years at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination</title>
          <description>Antibodies to Menactra vaccine were measured by the Serum bactericidal assay baby rabbit complement (SBA BR) Test.</description>
          <population>Menactra vaccine antibody titers were determined in the immunogenicity analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Pre-vaccination; N= 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="27" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="23" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Post-vaccination; N= 99, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="94" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="97" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Pre-vaccination; N= 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="43" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="66" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Post-vaccination; N= 99, 98, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="95" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Pre-vaccination; N= 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="92" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="89" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Post-vaccination; N= 99, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="98" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Pre-vaccination; N=100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="68" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="52" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Post-vaccination; N= 99, 97, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Baby Rabbit Complement (SBA BR) Geometric Mean Titers Before and Post Menactra Vaccination</title>
        <description>Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.</description>
        <time_frame>Day 0 and Day 30 post-vaccination</time_frame>
        <population>Geometric mean titers were determined in the immunogenicity analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2 to 11 Years Group</title>
            <description>Participants at age 2 to 11 years on enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Age 12 to 17 Years Group</title>
            <description>Participants aged 12 to 17 years at enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Age 18 to 55 Years Group</title>
            <description>Participants aged 18 to 55 years at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Baby Rabbit Complement (SBA BR) Geometric Mean Titers Before and Post Menactra Vaccination</title>
          <description>Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.</description>
          <population>Geometric mean titers were determined in the immunogenicity analysis set</population>
          <units>1/dilution (1/dil)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Pre-vaccination; N= 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" lower_limit="6.43" upper_limit="14.1"/>
                    <measurement group_id="O2" value="15.0" lower_limit="9.65" upper_limit="23.4"/>
                    <measurement group_id="O3" value="9.78" lower_limit="6.90" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Post-vaccination; N= 99, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1145" lower_limit="854" upper_limit="1536"/>
                    <measurement group_id="O2" value="1324" lower_limit="1002" upper_limit="1750"/>
                    <measurement group_id="O3" value="2261" lower_limit="1749" upper_limit="2924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Pre-vaccination; N= 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" lower_limit="7.01" upper_limit="14.0"/>
                    <measurement group_id="O2" value="17.9" lower_limit="12.2" upper_limit="26.2"/>
                    <measurement group_id="O3" value="56.9" lower_limit="36.6" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Post-vaccination; N= 99, 98, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610" lower_limit="392" upper_limit="949"/>
                    <measurement group_id="O2" value="2343" lower_limit="1563" upper_limit="3512"/>
                    <measurement group_id="O3" value="7486" lower_limit="5380" upper_limit="10417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Pre-vaccination; N= 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355" lower_limit="256" upper_limit="491"/>
                    <measurement group_id="O2" value="309" lower_limit="222" upper_limit="430"/>
                    <measurement group_id="O3" value="156" lower_limit="110" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Post-vaccination; N= 99, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1964" lower_limit="1607" upper_limit="2399"/>
                    <measurement group_id="O2" value="3190" lower_limit="2502" upper_limit="4067"/>
                    <measurement group_id="O3" value="3926" lower_limit="2855" upper_limit="5398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Pre-vaccination; N=100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="20.6" upper_limit="47.7"/>
                    <measurement group_id="O2" value="47.8" lower_limit="32.3" upper_limit="70.9"/>
                    <measurement group_id="O3" value="28.6" lower_limit="18.6" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (Post-vaccination; N= 99, 97, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1756" lower_limit="1240" upper_limit="2486"/>
                    <measurement group_id="O2" value="2538" lower_limit="1947" upper_limit="3307"/>
                    <measurement group_id="O3" value="3183" lower_limit="2360" upper_limit="4293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least a 4-fold Increase in Antibodies to Menactra Vaccine Antigens Post Vaccination</title>
        <description>Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.</description>
        <time_frame>Day 0 to 30 post-vaccination</time_frame>
        <population>Four-fold antibody increase were determined in the immunogenicity analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2 to 11 Years Group</title>
            <description>Participants at age 2 to 11 years on enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Age 12 to 17 Years Group</title>
            <description>Participants aged 12 to 17 years at enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Age 18 to 55 Years Group</title>
            <description>Participants aged 18 to 55 years at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 4-fold Increase in Antibodies to Menactra Vaccine Antigens Post Vaccination</title>
          <description>Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.</description>
          <population>Four-fold antibody increase were determined in the immunogenicity analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (N = 99, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="85" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="96" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N = 99, 98, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="91" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="96" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N = 99, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="89" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N = 99, 97, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="96" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="97" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Menactra Vaccination</title>
        <description>Solicited injection site: Pain, Erythema (Redness), and Swelling. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia</description>
        <time_frame>Day 0 to 7 post-vaccination</time_frame>
        <population>Safety parameters were assessed in the safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2 to 11 Years Group</title>
            <description>Participants at age 2 to 11 years on enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Age 12 to 17 Years Group</title>
            <description>Participants aged 12 to 17 years at enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Age 18 to 55 Years Group</title>
            <description>Participants aged 18 to 55 years at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Menactra Vaccination</title>
          <description>Solicited injection site: Pain, Erythema (Redness), and Swelling. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia</description>
          <population>Safety parameters were assessed in the safety analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="38" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 erythema (≥5 cm [2-11 years] or &gt;10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling (≥5 cm [2-11 years] or &gt;10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever (≥ 39.0°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="19" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (significant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise (significant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="12" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (significant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination (Day 0) to up to 6 months post vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Age 2 to 11 Years Group</title>
          <description>Participants at age 2 to 11 years on enrollment.</description>
        </group>
        <group group_id="E2">
          <title>Age 12 to 17 Years Group</title>
          <description>Participants aged 12 to 17 years at enrollment.</description>
        </group>
        <group group_id="E3">
          <title>Age 18 to 55 Years Group</title>
          <description>Participants aged 18 to 55 years at enrollment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E3" events="38" subjects_affected="38" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="100"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

